GYRE
Gyre Therapeutics Inc.
$7.47
+$0.22(+3.03%)
33
Overall
30
Value
36
Tech
--
Quality
Market Cap
$698.27M
Volume
64.27K
52W Range
$6.11 - $19.00
Target Price
$19.00
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $1.8M | $399.0K | $1.0M | $6.0K | -- | $20.9M | $7.3M | $102.3M | $113.5M | $105.8M | ||
| Total Revenue | $1.8M | $399.0K | $1.0M | $6.0K | -- | $20.9M | $7.3M | $102.3M | $113.5M | $105.8M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | $6.1M | $4.0M | $4.8M | $4.6M | $3.9M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $1.8M | $399.0K | $1.0M | $6.0K | -- | $14.9M | $85.6M | $97.5M | $108.8M | $101.9M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-15.6M | $-20.8M | $-22.8M | $-33.8M | $-57.3M | $78.3M | $95.2M | $88.3M | $89.6M | $85.6M | ||
| Research & Development | $6.0M | $11.6M | $12.8M | $21.5M | $43.9M | $53.0M | $68.9M | $16.7M | $13.8M | $12.0M | ||
| Research Expense | $6.0M | $11.6M | $12.8M | $21.5M | $43.9M | $53.0M | $68.9M | $16.7M | $13.8M | $12.0M | ||
| Selling, General & Administrative | $9.6M | $9.3M | $10.0M | $12.4M | $13.4M | $16.2M | $19.0M | $71.6M | $75.8M | $73.6M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | -- | -- | $54.2M | $61.2M | $57.5M | ||
| General & Administrative Expenses | $9.6M | $9.3M | $10.0M | $12.4M | $13.4M | $16.2M | $19.0M | $17.4M | $14.7M | $16.1M | ||
| Salaries & Wages | -- | -- | -- | $-2.6M | $-3.2M | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | -- | -- | $-200.0K | $-100.0K | -- | -- | -- | $900.0K | $1.0M | $1.3M | ||
| Depreciation & Amortization | -- | -- | $-200.0K | $-100.0K | -- | -- | -- | $900.0K | -- | -- | ||
| Amortization | -- | -- | -- | -- | -- | -- | -- | $200.0K | $100.0K | $47.0K | ||
| Other Operating Expenses | $-15.6M | -- | -- | $-85.0K | $-253.0K | $-1.4M | $-1.7M | $-20.0K | $176.0M | $85.7M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-13.8M | $-20.4M | $-21.8M | $-33.8M | $-57.3M | $-57.4M | $-87.9M | $9.2M | $-67.2M | $16.2M | ||
| EBITDA | $-13.3M | $-20.0M | $-21.6M | $-33.7M | $-57.1M | $-57.2M | $31.7M | $10.3M | $20.3M | $17.8M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $1.5M | -- | -- | -- | -- | -- | $122.4K | $299.0K | $-1.0M | $-1.5M | ||
| Net Non-Operating Interest Income/Expense | $-1.5M | -- | $215.0K | $2.2M | $2.1M | $561.0K | $39.0K | $-726.0K | $1.0M | $1.5M | ||
| Other Income/Expense | $91.0K | -- | $-47.0K | $-1.5M | $-7.0K | $91.0K | $78.0K | $-517.0K | $14.1M | $-5.4M | ||
| Other Special Charges | $-91.0K | -- | $50.0K | $1.6M | $7.0K | $-91.0K | $-78.0K | $-517.0K | $-10.8M | $5.5M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | $4.2M | $1.0M | -- | -- | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | $-4.2M | $-1.0M | $-600.0K | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-13.8M | $-20.4M | $-21.8M | $-33.8M | $-57.3M | $-57.4M | $29.7M | $9.2M | $19.2M | $16.2M | ||
| Pre-Tax Income | $-15.3M | $-20.4M | $-21.8M | $-33.8M | $-57.3M | $-57.4M | $-87.9M | $9.4M | $-77.0M | $23.2M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | -- | -- | -- | -- | $6.2M | $5.1M | $8.5M | $5.3M | ||
| NET INCOME | ||||||||||||
| Net Income | $-14.8M | $-16.9M | $-21.6M | $-30.1M | $-55.2M | $-56.2M | $23.4M | $2.3M | $-92.9M | $12.1M | ||
| Net Income (Continuing Operations) | $-14.8M | $-16.9M | $-21.6M | $-30.1M | $-55.2M | $-56.2M | $-87.9M | $4.3M | $-85.5M | $17.9M | ||
| Net Income (Discontinued Operations) | $-14.8M | $-16.9M | $-21.6M | $-30.1M | $-55.2M | $-56.2M | $23.4M | $2.3M | $-92.9M | $12.1M | ||
| Net Income (Common Stockholders) | $-14.8M | $-16.9M | $-25.5M | $-30.1M | $-55.2M | $-56.2M | $23.4M | $2.3M | $-92.9M | $12.1M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-65.3M | -- | -- | -- | ||
| TOTALS | ||||||||||||
| Total Expenses | $-15.6M | $-20.8M | $-22.8M | $-33.8M | $-57.3M | $84.4M | $102.6M | $93.1M | $94.2M | $89.5M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $16.8M | $3.0M | $13.0M | $42.6M | $800.3K | $1.3M | $2.0M | $2.1M | $65.8M | $85.1M | ||
| Average Shares Outstanding (Diluted) | $16.9M | $3.0M | $11.0M | $42.6M | $799.7K | $1.3M | $2.0M | $2.1M | $65.8M | $102.3M | ||
| Shares Outstanding | $2.9M | $253.5K | $45.2M | $45.5M | $805.1K | $2.1M | $2.1M | $2.5M | $85.4M | $93.6M | ||
| Basic EPS | -- | -- | -- | -- | -- | $-43.95 | $-43.05 | $-3.9 | $-1.41 | $0.14 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-43.95 | $-43.05 | $-3.9 | $-1.41 | $0.14 | ||
| Diluted EPS | $-0.88 | $-5.72 | $-1.96 | $-0.70 | $-69 | $-43.95 | $-43.05 | $-3.9 | $-1.41 | $0.05 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-3.9 | $-1.41 | $0.05 | ||
| Dividend Per Share | -- | -- | -- | -- | -- | -- | -- | $3.6 | -- | -- | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | $4.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of Business | -- | -- | -- | -- | -- | -- | -- | -- | $-2.7M | -- | ||
| Gain On Sale Of P P E | -- | -- | $-3.0K | $-116.0K | -- | -- | -- | $-4.0K | $-628.0K | $-66.0K | ||
| Minority Interests | -- | -- | -- | -- | -- | -- | -- | $-2.0M | $-7.5M | $-5.8M | ||
| Net Income From Other Gains Losses | $518.0K | $3.5M | $261.0K | $3.8M | $2.1M | $1.1M | $-39.0K | -- | -- | -- | ||
| Other Gand A | $9.6M | $9.3M | $10.0M | $12.4M | $13.4M | $16.2M | $19.0M | $17.4M | $14.7M | $16.1M | ||
| Otherunder Preferred Stock Dividend | -- | -- | $4.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | -- | -- | $4.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $9.6M | $9.3M | $10.0M | $12.4M | $13.4M | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | $4.2M | $1.0M | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GYRE | $7.47 | +3.0% | 64.27K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |